共 50 条
- [1] "Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (05): : 301 - 310
- [2] SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (03): : 168 - 177
- [3] SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (09): : 573 - 582
- [4] SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : 613 - 620
- [5] SOHO State of the Art Updates and Next Questions: Myelofibrosis [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 191 - 199
- [6] SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (12): : 869 - 877
- [7] SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (01): : 1 - 14
- [8] SOHO State of the Art Updates and Next Questions: IDH Inhibition [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (09): : 567 - 572
- [9] SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (02): : 81 - 90
- [10] New Series: SOHO 'State of the Art Updates and Next Questions' [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (08): : 463 - 463